2025 I 2024 I 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011

2025

Wagner MJ, Pimenta EM, Sweeney NW, Loggers ET, Roberts JL, Brinkman E, Chen EY, Ricciotti R, Haddox CL, Berg R, Yilma B, Stoppler MC, Chen JL, Cranmer LD. Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic Targets. JCO Precis Oncol. 2025 Mar;9:e2400592. doi: 10.1200/PO-24-00592. Epub 2025 Mar 21. PMID: 40117529; PMCID: PMC11949235.

2024

Loggers ET, Chugh R, Federman N, Hartner L, Riedel RF, Cho S, Hyslop D, Lim A, Oton AB, Oktay KH. Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study. Cancer. 2024 May 4. doi: 10.1002/cncr.35324. Epub ahead of print. PMID: 38703010.

Wagner MJ, Ravi V, Schaub SK, Kim EY, Sharib J, Mogal H, Park M, Tsai M, Duarte-Bateman D, Tufaro A, Loggers ET, Cranmer LD, Chau B, Hassett MJ, Grilley-Olson J, Paulson KG. Incidence and Presenting Characteristics of Angiosarcoma in the US, 2001-2020. JAMA Netw Open. 2024 Apr 1;7(4):e246235. doi: 10.1001/jamanetworkopen.2024.6235. PMID: 38607625; PMCID: PMC11015348.

2023

Attia S, Bolejack V, Ganjoo KN, George S, Agulnik M, Rushing D, Loggers ET, Livingston MB, Wright J, Chawla SP, Okuno SH, Reinke DK, Riedel RF, Davis LE, Ryan CW, Maki RG. A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results. Cancer Med. 2023 Jan;12(2):1532-1539. doi: 10.1002/cam4.5044. Epub 2022 Aug 10. PMID: 35950293; PMCID: PMC9883574. [original work]

Gounder M, Ratan R, Alcindor T, Schöffski P, van der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, Attia S, Chawla S, D'Amato G, Federman N, Merriam P, Van Tine BA, Vincenzi B, Benson C, Bui NQ, Chugh R, Tinoco G, Charlson J, Dileo P, Hartner L, Lapeire L, Mazzeo F, Palmerini E, Reichardt P, Stacchiotti S, Bailey HH, Burgess MA, Cote GM, Davis LE, Deshpande H, Gelderblom H, Grignani G, Loggers E, Philip T, Pressey JG, Kummar S, Kasper B. Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors. N Engl J Med. 2023 Mar 9;388(10):898-912. doi: 10.1056/NEJMoa2210140. PMID: 36884323; PMCID: PMC11225596.

Cranmer LD, Lu Y, Heise RS, Ballman KV, Loggers ET, Pollack SM, Wagner MJ, Reinke DK, Schöffski P, Tap WD. Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406). Clin Cancer Res. 2023 Mar 14;29(6):1068-1076. doi: 10.1158/1078-0432.CCR-22-1564. PMID: 36622694. [original work]

Chau B, Loggers ET, Cranmer LD, Mogal H, Sharib JM, Kim EY, Schaub SK, Paulson KG, Linden HM, Specht JM, Kim JN, Javid SH, Wagner MJ. Secondary Breast Angiosarcoma After a Primary Diagnosis of Breast Cancer: A Retrospective Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database. Am J Clin Oncol. 2023 Dec 1;46(12):567-571. doi: 10.1097/COC.0000000000001045. Epub 2023 Sep 19. PMID: 37725702; PMCID: PMC10841185. [original work]

Seo YD, Lu H, Black G, Smythe K, Yu Y, Hsu C, Ng J, Hermida de Viveiros P, Warren EH, Schroeder BA, O'Malley RB, Cranmer LD, Loggers ET, Wagner MJ, Bonham L, Pillarisetty VG, Kane G, Berglund P, Hsu FJ, Mi X, Alexiev BA, Pierce RH, Riddell SR, Jones RL, Ter Meulen J, Kim EY, Pollack SM. Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma: A Phase 1 Nonrandomized Controlled Trial. JAMA Oncol. 2023 Dec 1;9(12):1660-1668. doi: 10.1001/jamaoncol.2023.4015. PMID: 37824131; PMCID: PMC10570919. [original work]

Paulson KG, Ravi V, Rubin BP, Park M, Loggers ET, Cranmer LD, Wagner MJ. Incidence, demographics, and survival of malignant hemangioendothelioma in the United States. Cancer Med. 2023 Jul;12(14):15101-15106. doi: 10.1002/cam4.6181. Epub 2023 Jun 1. PMID: 37260142; PMCID: PMC10417180. [original work]

2021

Wagner MJ, Pollack SM, Cranmer LD, Thompson MJ, Maxwell S, Wright S, Khaki AR, Madeleine MM, Grivas P, Kuderer NM, Lyman GH, Loggers ET. Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis. Cancer Invest. 2021 Apr;39(4):315-320. doi: 10.1080/07357907.2021.1903914. Epub 2021 Mar 26. PMID: 33720792. [original work]

2020

Hammer KJ, Copeland VC, Loggers ET, Pollack SM, Wagner MJ, Cranmer LD. Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas. Am J Clin Oncol. 2020 Jun;43(6):446-451. doi: 10.1097/COC.0000000000000690. PMID: 32235164. [original work]

Cranmer, Lee D; Chau, Bonny; Thompson, Matthew J.; Loggers, Elizabeth T.; Pollack, Seth M.; Wagner, Michael J.; Kim, Teresa S.; Kim, Edward Y.; Kane, Gabrielle M.; Pavey, Gabriel J. Impact of nodal involvement on survival outcomes in chondrosarcoma: retrospective cohort analysis of Surveillance, Epidemiology, and End Results (SEER) database (2004–2015). International Journal of Surgery Oncology 2020 August; 5(4). DOI: 10.1097/IJ9.0000000000000091 [original work]

Wagner MJ, Chau B, Loggers ET, Pollack SM, Kim TS, Kim EY, Thompson MJ, Harwood JL, Cranmer LD. Long-term Outcomes for Extraskeletal Myxoid Chondrosarcoma: A SEER Database Analysis. Cancer Epidemiol Biomarkers Prev. 2020 Nov;29(11):2351-2357. doi: 10.1158/1055-9965.EPI-20-0447. Epub 2020 Aug 20. PMID: 32856598. [original work]

Riedel RF, Ballman KV, Lu Y, Attia S, Loggers ET, Ganjoo KN, Livingston MB, Chow W, Wright J, Ward JH, Rushing D, Okuno SH, Reed DR, Liebner DA, Keedy VL, Mascarenhas L, Davis LE, Ryan C, Reinke DK, Maki RG. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. Oncologist. 2020 Nov;25(11):e1655-e1662. doi: 10.1634/theoncologist.2020-0679. Epub 2020 Aug 20. PMID: 32701199; PMCID: PMC7648334. [original work]

Pollack SM, Redman MW, Baker KK, Wagner MJ, Schroeder BA, Loggers ET, Trieselmann K, Copeland VC, Zhang S, Black G, McDonnell S, Gregory J, Johnson R, Moore R, Jones RL, Cranmer LD. Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial. JAMA Oncol. 2020 Nov 1;6(11):1778-1782. doi: 10.1001/jamaoncol.2020.3689. PMID: 32910151; PMCID: PMC7489365. [original work]

Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 Nov;21(11):1423-1432. doi: 10.1016/S1470-2045(20)30451-4. Epub 2020 Oct 6. PMID: 33035459. [original work]

2019

Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol. 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374. Epub 2019 Apr 23. PMID: 31013172; PMCID: PMC7799443. [original work]

Hartvigson PE, Velamoor GR, Loggers ET, Kim E. Cardiac Angiosarcoma from a Saphenous Vein Coronary Artery Bypass Graft. Cureus. 2019 Aug 27;11(8):e5503. doi: 10.7759/cureus.5503. PMID: 31667037; PMCID: PMC6816531. [case report]

2018

Pierce DB, Johnson GE, Monroe E, Loggers ET, Jones RL, Pollack SM, Padia SA. Safety and Efficacy Outcomes of Embolization in Hepatic Sarcomas. AJR Am J Roentgenol. 2018 Jan;210(1):175-182. doi: 10.2214/AJR.16.17573. Epub 2017 Nov 1. PMID: 29090997. [original work]

Wagner MJ, Cranmer LD, Loggers ET, Pollack SM. Propranolol for the treatment of vascular sarcomas. J Exp Pharmacol. 2018 Sep 6;10:51-58. doi: 10.2147/JEP.S146211. PMID: 30233257; PMCID: PMC6130307. [review]

Wagner MJ, Ricciotti RW, Mantilla J, Loggers ET, Pollack SM, Cranmer LD. Response to PD1 inhibition in conventional chondrosarcoma. J Immunother Cancer. 2018 Sep 25;6(1):94. doi: 10.1186/s40425-018-0413-z. PMID: 30253794; PMCID: PMC6156853.. [original work]

2017

Pollack SM, He Q, Yearley JH, Emerson R, Vignali M, Zhang Y, Redman MW, Baker KK, Cooper S, Donahue B, Loggers ET, Cranmer LD, Spraker MB, Seo YD, Pillarisetty VG, Ricciotti RW, Hoch BL, McClanahan TK, Murphy E, Blumenschein WM, Townson SM, Benzeno S, Riddell SR, Jones RL. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer. 2017 Sep 1;123(17):3291-3304. doi: 10.1002/cncr.30726. Epub 2017 May 2. PMID: 28463396; PMCID: PMC5568958. [original work]

2016

Rainey D, Berriochoa J, Korpak A, Zeng J, Loggers ET, Jones RL, Patel S. Treatment of resectable intrathoracic sarcomas: a single institution experience over twenty years. J Radiat Oncol. 2016;5:169-177. doi: 10.1007/s13566-015-0236-1. Epub 2015 Dec 16. PMID: 27335629; PMCID: PMC4893388. [original work]

Cranmer LD, Loggers ET, Pollack SM. Pazopanib in the management of advanced soft tissue sarcomas. Ther Clin Risk Manag. 2016 Jun 9;12:941-55. doi: 10.2147/TCRM.S84792. PMID: 27354810; PMCID: PMC4907704. [review]

2015

Petek BJ, Loggers ET, Pollack SM, Jones RL. Trabectedin in soft tissue sarcomas. Mar Drugs. 2015 Feb 12;13(2):974-83. doi: 10.3390/md13020974. PMID: 25686274; PMCID: PMC4344612. [review]

2014

Bremjit PJ, Jones RL, Chai X, Kane G, Rodler ET, Loggers ET, Pollack SM, Pillarisetty VG, Mann GN. A contemporary large single-institution evaluation of resected retroperitoneal sarcoma. Ann Surg Oncol. 2014 Jul;21(7):2150-8. doi: 10.1245/s10434-014-3616-7. Epub 2014 Mar 11. PMID: 24615180. [original work]

Jour G, Scarborough JD, Jones RL, Loggers E, Pollack SM, Pritchard CC, Hoch BL. Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics. Hum Pathol. 2014 Aug;45(8):1563-71. doi: 10.1016/j.humpath.2014.04.012. Epub 2014 Apr 24. PMID: 24908143. [original work]

Chang AE, Chai X, Pollack SM, Loggers E, Rodler E, Dillon J, Parvathaneni U, Moe KS, Futran N, Jones RL. Analysis of clinical prognostic factors for adult patients with head and neck sarcomas. Otolaryngol Head Neck Surg. 2014 Dec;151(6):976-83. doi: 10.1177/0194599814551539. Epub 2014 Sep 25. PMID: 25257906. [original work]

2013

Constantinidou A, Pollack S, Loggers E, Rodler E, Jones RL. The evolution of systemic therapy in sarcoma. Expert Rev Anticancer Ther. 2013 Feb;13(2):211-23. doi: 10.1586/era.12.161. PMID: 23406562. [review]

Schroeder BA, Rodler ET, Loggers ET, Pollack SM, Jones RL. Clinical benefit of trabectedin in uterine adenosarcoma. Med Oncol. 2013 Jun;30(2):501. doi: 10.1007/s12032-013-0501-3. Epub 2013 Feb 28. PMID: 23456619. [original work]

Chang AE, Mann GN, Hoch B, Loggers ET, Pollack SM, Kolokythas O, Jones RL. Multiple liver abscess formation and primary gastrointestinal stromal tumor. Rare Tumors. 2013 Sep 4;5(3):e51. doi: 10.4081/rt.2013.e51. PMID: 24179663; PMCID: PMC3804826. [original work]

2012

Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU 3rd, Jones RL, Yee C. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One. 2012;7(2):e32165. doi: 10.1371/journal.pone.0032165. Epub 2012 Feb 27. PMID: 22384167; PMCID: PMC3288075. [original work]

Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, Loggers ET, Rodler E, Eary JF, Conrad EU 3rd, Jones RL, Yee C. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer. 2012 Sep 15;118(18):4564-70. doi: 10.1002/cncr.27446. Epub 2012 Feb 22. PMID: 22359263; PMCID: PMC3361576. [original work]

Ferreira BP, Rodler ET, Loggers ET, Pollack SM, Jones RL. Systemic therapy in primary angiosarcoma of the spleen. Rare Tumors. 2012 Oct 10;4(4):e55. doi: 10.4081/rt.2012.e55. Epub 2012 Nov 13. PMID: 23372919; PMCID: PMC3557569.

2011

Pollack SM, Loggers ET, Rodler ET, Yee C, Jones RL. Immune-based therapies for sarcoma. Sarcoma. 2011;2011:438940. doi: 10.1155/2011/438940. Epub 2011 Jan 23. PMID: 21331153; PMCID: PMC3034923. [review]